535. Evaluation of the BioFire Blood Culture Identification (BCID2) panel for transplant recipients with a bloodstream infection
Palacios C, Peaper D, Malinis M, Malinis M, Perreault S, Cohen E, Vogel J, Azar M. 535. Evaluation of the BioFire Blood Culture Identification (BCID2) panel for transplant recipients with a bloodstream infection. Open Forum Infectious Diseases 2022, 9: ofac492.588. PMCID: PMC9752191, DOI: 10.1093/ofid/ofac492.588.Peer-Reviewed Original ResearchBone marrow transplant recipientsTransplant recipientsBloodstream infectionsBlood culturesPositive blood culturesClinical trialsPrimary investigatorSolid organ recipientsMarrow transplant recipientsRetrospective chart reviewYear of transplantationAntimicrobial susceptibility resultsBlood Culture Identification PanelBSI eventsChart reviewOptimal therapyOrgan recipientsMean ageMultiplex PCR panelSame patientGeneral populationPolymicrobial culturesCandida sppPeripheral sitesRecipientsAntiviral Treatment of Coronavirus Disease-2019 Pneumonia
Radcliffe C, Malinis M, Azar M. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. Clinics In Chest Medicine 2022, 44: 279-297. PMID: 37085220, PMCID: PMC9701636, DOI: 10.1016/j.ccm.2022.11.008.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus diseaseCoronavirus 2 infectionDirect acting antiviralsAdditional clinical trialsReal-world studyCOVID-19Acting antiviralsAntiviral treatmentTherapeutic optionsAvailable therapiesClinical trialsDisease progressionInpatient treatmentHigh riskEarly pandemicMonoclonal antibodiesDiseaseTreatmentMorbidityPandemicPneumoniaOutpatientsReal‐world experience with available, outpatient COVID‐19 therapies in solid organ transplant recipients during the omicron surge
Radcliffe C, Palacios CF, Azar MM, Cohen E, Malinis M. Real‐world experience with available, outpatient COVID‐19 therapies in solid organ transplant recipients during the omicron surge. American Journal Of Transplantation 2022, 22: 2458-2463. PMID: 35583664, PMCID: PMC9348251, DOI: 10.1111/ajt.17098.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOral antiviral agentsOrgan transplant recipientsOutpatient therapyTransplant recipientsAntiviral agentsCOVID-19-related morbidityMonoclonal antibodiesKidney transplant recipientsRate of hospitalizationCOVID-19 therapyReal-world effectivenessSARS-CoV-2 pandemicCOVID-19 diagnosisModerate diseaseRetrospective reviewMean ageOutpatient settingClinical trialsSubstantial burdenTherapyCoronavirus diseaseMean timeHealthcare systemReal-world experience